Melanoma Clinical Trial
Official title:
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
The purpose of this study is to image skin and skin lesions with a new imaging technology
called "multiwavelength and coherence confocal reflectance microscopy". This technology uses
low intensity laser to image below the surface of the skin. This technology may provide a
new way of looking at skin and skin lesions. The goal of this study is to evaluate the
images of your skin taken by this microscope.
The techniques being evaluated in this study use multi wavelength and coherence confocal
reflectance microscopy invivo. The term "in vivo" means in/on a living subject. In this
study you will be the living subject and the multi wave length and coherence confocal
microscope will be placed on your skin to look at your skin lesions and your normal skin.
The confocal microscope uses a weak laser light and a sophisticated lens to image the
individual cells that make up the skin. Your lesion will be photographed with high
resolution photography. An area near your skin lesion that is clinically normal will also be
imaged in the same manner.
Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during
a single patient visit. The lesion will be photographed with high resolution photography and
surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the
same manner.
The lesion will then be prepped for RCM imaging. A skin contact device consisting of a metal
ring and template will be applied to the skin surrounding the lesion of interest with a
disposable medicalgrade adhesive plastic disc. A wetting solution will be placed into the
metal ring. The wetting solutions include water, mineral oil and other over the counter
products (e.g. hairstyling gel and moisturizing agents). Application of these agents
diminishes artifacts caused by light scattering at the skin surface. RCM images of the
lesion will be captured through the contact device using the Vivascope 1500m surface
confocal microscope provided by Lucid Technologies, Inc. Two types of images will be
collected, VivaBlocks and VivaStacks. VivaBlocks are a 4x4 mosaic of confocal images that
measure 2mm x 2mm in total area. These VivaBlock images are optically combined or "stitched"
together by the VivaScope 1500m to create a seamless representation of 4 mm 2 area at a
specific depth within the skin. VivaStacks are eight 0.5mm x 0.5mm confocal images taken at
3 micron intervals from the keratin layer to the superficial dermis. VivaStacks and
VivaBlocks will be acquired for both the skin lesion and for the clinically uninvolved area
of the skin. The total estimated imaging time for a patient in this study is about 30
minutes for the lesion and the clinically uninvolved site.
The confocal imaging session and the dermatologic visit for the punch biopsy do not have to
occur during the same patient visit. All lesion images will be saved on a network server for
later review and analysis. All imaging will be completed by trained research staff familiar
with confocal imaging.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|